share_log

Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting)

Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting)

Clearmind Medicine | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  12/07 06:05

Moomoo AI 已提取核心信息

Clearmind Medicine has scheduled its Annual and Special Meeting of Shareholders for January 6, 2025. The meeting will be held virtually via Zoom. Shareholders as of the record date, November 28, 2024, are entitled to vote.Key agenda items include the presentation of audited financial statements for the fiscal year ended October 31, 2023, fixing the number of directors at five, election of directors, and appointment of Brightman Almagor Zohar & Co. as auditors. Shareholders will also vote on the approval of the omnibus equity incentive plan and a potential share consolidation.The board recommends voting in favor of all resolutions. Proxies must be submitted by January 2, 2025. The meeting aims to align shareholder interests with company growth and governance objectives.
Clearmind Medicine has scheduled its Annual and Special Meeting of Shareholders for January 6, 2025. The meeting will be held virtually via Zoom. Shareholders as of the record date, November 28, 2024, are entitled to vote.Key agenda items include the presentation of audited financial statements for the fiscal year ended October 31, 2023, fixing the number of directors at five, election of directors, and appointment of Brightman Almagor Zohar & Co. as auditors. Shareholders will also vote on the approval of the omnibus equity incentive plan and a potential share consolidation.The board recommends voting in favor of all resolutions. Proxies must be submitted by January 2, 2025. The meeting aims to align shareholder interests with company growth and governance objectives.
Clearmind Medicine已计划于2025年1月6日举行年度和特别股东大会。会议将通过Zoom虚拟举行。截至记录日期,即2024年11月28日,股东有权投票。关键议程项目包括列报截至2023年10月31日的财政年度的经审计的财务报表、将董事人数定为五名、选举董事以及任命布莱曼·阿尔玛戈尔·佐哈尔公司为审计师。股东们还将就综合股权激励计划的批准和可能的股票整合进行投票。董事会建议对所有决议投赞成票。代理必须在 2025 年 1 月 2 日之前提交。该会议旨在使股东利益与公司增长和治理目标保持一致。
Clearmind Medicine已计划于2025年1月6日举行年度和特别股东大会。会议将通过Zoom虚拟举行。截至记录日期,即2024年11月28日,股东有权投票。关键议程项目包括列报截至2023年10月31日的财政年度的经审计的财务报表、将董事人数定为五名、选举董事以及任命布莱曼·阿尔玛戈尔·佐哈尔公司为审计师。股东们还将就综合股权激励计划的批准和可能的股票整合进行投票。董事会建议对所有决议投赞成票。代理必须在 2025 年 1 月 2 日之前提交。该会议旨在使股东利益与公司增长和治理目标保持一致。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息